Cartesian Therapeutics Inc (RNAC)
17.62
+1.85
(+11.73%)
USD |
NASDAQ |
Jul 03, 16:00
Cartesian Therapeutics Research and Development Expense (Annual): 71.84M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 71.84M |
| December 31, 2022 | 72.38M |
| December 31, 2021 | 68.74M |
| December 31, 2020 | 54.50M |
| December 31, 2019 | 42.74M |
| Date | Value |
|---|---|
| December 31, 2018 | 47.69M |
| December 31, 2017 | 45.16M |
| December 31, 2016 | 29.70M |
| December 31, 2015 | 22.98M |
| December 31, 2014 | 10.49M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
42.74M
Minimum
2019
72.38M
Maximum
2022
62.04M
Average
68.74M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Marinus Pharmaceuticals Inc | 99.39M |
| Adial Pharmaceuticals Inc | 1.267M |
| Poseida Therapeutics Inc | 156.77M |
| Viracta Therapeutics Inc | 33.37M |
| Biomea Fusion Inc | 102.55M |